Can a Person Be on Antibiotics for Life?

Some people do take antibiotics for years or even the rest of their lives, and in certain medical situations this is standard practice rather than an extreme measure. The conditions that call for indefinite antibiotic therapy range from immune deficiencies and missing spleens to chronic infections that surgery cannot fully clear. The practice dates back to at least the 1940s and has expanded considerably since then, though it comes with real trade-offs in terms of gut health, organ stress, and the emergence of drug-resistant bacteria.

Conditions That Call for Indefinite Antibiotics

Long-term antibiotic use falls into a few broad categories: preventing infections in people whose immune systems cannot fight them off normally, suppressing chronic infections that resist a cure, and using certain antibiotics for their anti-inflammatory properties rather than their germ-killing ability. The specific conditions are more varied than most people expect.

People who have had their spleen removed are a classic example. The spleen filters bacteria from the bloodstream, and without it, certain encapsulated organisms can cause overwhelming, rapidly fatal sepsis. For that reason, daily low-dose antibiotics are often prescribed after splenectomy, sometimes for years and sometimes indefinitely, alongside vaccination.

¹

Rheumatic fever is another well-established case. People who have had an episode of rheumatic fever are at high risk of recurrence every time they catch a strep throat infection, and repeated episodes progressively damage the heart valves. The American Heart Association recommends continuous antibiotic prophylaxis with penicillin for these patients, with the duration depending on cardiac involvement. People with documented heart valve damage may stay on prophylaxis for ten years or longer, and in some guidelines, for life.

² A large randomized trial found that secondary antibiotic prophylaxis reduced the risk of echocardiographic progression of latent rheumatic heart disease from about 8% to under 1% over two years.³ A Cochrane meta-analysis of six trials confirmed that antibiotics cut the risk of rheumatic fever recurrence substantially.⁴

Primary immune deficiencies represent perhaps the broadest group of lifelong antibiotic users. People born with conditions like chronic granulomatous disease, complement deficiencies, or certain T-cell defects face recurrent, sometimes life-threatening infections throughout their lives. Prophylactic antibiotics have transformed clinical outcomes in many of these conditions, often used alongside immunoglobulin replacement therapy.

⁵ For patients with incomplete antibody deficiency, a trial comparing long-term antibiotic prophylaxis to immunoglobulin replacement found similar infection rates in both groups, suggesting antibiotics alone can be a reasonable option for some of these patients.⁶ A German evidence-based guideline noted that long-term azithromycin given three times a week for two years reduced respiratory flare-ups in primary antibody deficiency patients compared to placebo.⁷

Cystic fibrosis patients are another group often on antibiotics for decades. Chronic lung colonization with Pseudomonas aeruginosa is common, and inhaled antibiotics given over months and years help slow lung function decline and reduce flare-ups. A Cochrane review found limited but positive evidence supporting this practice for up to about three years, which is as long as the longest trials ran.

⁸ An observational study of adult cystic fibrosis patients started on long-term low-dose azithromycin found that the median rate of lung function decline reversed from a loss of about 4% per year to a slight gain, with improvements in weight as well.⁹

Suppressive Therapy for Incurable Infections

Not every infection can be wiped out with a finite course of treatment and surgery. When it cannot, doctors sometimes pivot to what is called suppressive antibiotic therapy: the goal shifts from curing the infection to keeping it quiet enough that the patient can function. This is prescribed when an infection is presumed to be incurable by a defined course of treatment or source control.

¹⁰

Prosthetic joint infections are a common scenario. If someone has a hip or knee replacement that becomes infected and cannot be cured with surgery, long-term oral antibiotics may be the only option to keep the joint functional and the infection under control. This approach is considered reasonable for patients with persistent infection or multiple comorbidities that make further surgery too risky.¹¹ The evidence here is honest about its limitations. An older study of thirteen patients on suppressive therapy after prosthetic joint infection found that only three managed to keep their prostheses over a roughly three-year follow-up, with ten requiring removal for recurrent infection. Nearly 40% experienced side effects that required switching the antibiotic regimen.¹² That study was small and old, and more recent reviews describe suppressive therapy as a viable option for selected patients, but it underscores an important point: “lifelong” does not always mean “lifelong and working perfectly.” Sometimes it means “lifelong and managing a slow deterioration.”

¹³

Recurrent urinary tract infections in people who self-catheterize are another situation where long-term daily antibiotics have proven effective. A large randomized trial found that daily low-dose prophylaxis reduced UTI incidence by about half over twelve months.

¹⁴ However, that same trial noted a public health concern: the emergence of resistant urinary bacteria during prophylaxis may complicate future UTI management.¹⁵ A separate study of recurrent UTI patients who received continuous prophylactic antibiotics found significantly fewer UTI episodes, emergency room visits, and hospital admissions.¹⁶

Antibiotics Used for Anti-Inflammatory Effects

Some antibiotics have landed in long-term use for reasons that have little to do with killing germs. Azithromycin and other macrolides, for instance, have anti-inflammatory properties that benefit people with bronchiectasis. Minocycline sees widespread long-term use in dermatology. Ciprofloxacin and metronidazole are prescribed for inflammatory bowel disease. In these cases, the antibiotic is being used as an immune-modulating agent, and patients may be on it for years without having an active bacterial infection at all.

¹⁷

This is worth knowing because if you or someone you know is on “antibiotics for years” for something like acne or bronchiectasis, the treatment rationale is different from prophylaxis against a lethal infection. The drug is pulling double duty, and the question of how long to continue is weighed differently by doctors compared to a post-splenectomy patient on daily penicillin. The threshold for reconsidering or tapering is lower, because the stakes of stopping are usually less severe.

What Happens to Your Body on Years of Antibiotics

The most predictable consequence of long-term antibiotic use is disruption to the gut microbiome, the ecosystem of bacteria living in your intestines. Antibiotics do not distinguish well between the bacteria causing trouble and the ones keeping you healthy. Research has found that some antibiotic classes leave marks on the microbiome for far longer than anyone initially expected.

A large study linking individual-level prescription records to gut microbiome composition found that antibiotic use up to eight years before sampling was still associated with altered abundance of gut bacterial species. Clindamycin, fluoroquinolones, and flucloxacillin accounted for most of the lasting changes, while penicillin V and nitrofurantoin were associated with fewer long-term effects. Even a single course four to eight years earlier was linked to altered abundance of roughly one in ten species studied.

¹⁸ Another study found that microbial diversity remained significantly lower for up to four years after macrolides and lincosamides, and for at least a year after beta-lactams and quinolones.¹⁹

The practical consequences of a disrupted microbiome include increased susceptibility to Clostridioides difficile infection (a serious, sometimes life-threatening gut infection), metabolic disruption, and impaired immune function.²⁰ Among specific antibiotics, clindamycin and later-generation cephalosporins carry the greatest risk for C. diff, while minocycline and doxycycline carry the lowest.²¹ This is one reason why the choice of which antibiotic to use for long-term therapy matters enormously. A doctor picking a drug for years of prophylaxis will lean toward agents with a lighter microbiome footprint and a lower C. diff risk.

Beyond the gut, kidney damage is a real concern with some antibiotic classes over time. Drug-induced nephrotoxicity accounts for a large share of acute kidney injury in hospitalized patients, and antibiotics are among the most common culprits. Mechanisms include direct tubular injury, allergic-type inflammation in the kidneys, and crystal deposition.²² For patients on lifelong therapy, doctors typically choose oral agents with well-established safety profiles and monitor kidney function periodically.

Antibiotic Resistance and the Biofilm Problem

The concern that keeps infectious disease specialists up at night about lifelong antibiotic use is resistance. Every time antibiotics are present in the body, they create selection pressure: susceptible bacteria die, while any that carry or develop resistance genes survive and multiply. This happens not just at the site of infection but throughout the body, particularly in the gut, which serves as a massive reservoir. Antibiotic-resistant strains can persist in the body long after the selective pressure ends.

²³

Biofilms add another layer of difficulty. Many chronic infections, particularly those involving prosthetic joints or implanted devices, are maintained by bacteria living in structured communities called biofilms. Bacteria in biofilms are inherently more tolerant of antibiotics than their free-floating counterparts. Worse, biofilms harbor “persister cells” that enter a dormant state, survive antibiotic exposure, and repopulate the infection site once treatment stops. Regular antibiotic exposure has been shown to select for increased proportions of resistant strains, and the persister cell population may contribute to this ratcheting effect.²⁴ This is fundamentally why some infections become “incurable” in the first place and why suppressive therapy remains suppressive rather than curative: you cannot sterilize a biofilm with antibiotics alone, but you can keep the bacteria from breaking out into the bloodstream or surrounding tissue in dangerous numbers.

How Doctors Monitor Long-Term Therapy

Putting someone on indefinite antibiotics is not a set-and-forget decision. Depending on the drug and the condition, monitoring can include regular blood counts, kidney and liver function tests, and drug level measurements. For drugs with narrow safety margins, like linezolid (used in some resistant bone and joint infections), proactive therapeutic drug monitoring with weekly blood level checks has been studied as a way to manage long-term treatment safely and avoid toxicity to blood cells.

²⁵

For lower-risk drugs like oral penicillin or trimethoprim, the monitoring is less intense but still ongoing. Periodic urine cultures or sputum samples may be checked to watch for the emergence of resistant organisms. If resistance develops, the antibiotic may need to be switched, which is straightforward when alternative agents exist but becomes a serious problem when options are already limited. The patient’s overall clinical picture, including weight changes, frequency of infections that break through prophylaxis, and quality of life, is reassessed regularly. Lifelong therapy does not mean the prescription was written once and never revisited.

Is It Cost-Effective?

One argument in favor of long-term antibiotic prophylaxis is economic. For conditions where the alternative is repeated hospitalization for serious infections, daily oral antibiotics are extraordinarily cheap by comparison. An analysis framed it bluntly: in Australia, a single day in hospital costs over $600, while a week of inpatient treatment runs over $4,000. The cheapest oral antibiotics cost a few dollars a week, meaning one week of inpatient care is equivalent in cost to roughly 9,000 days of prophylaxis.¹⁷ Even the most expensive oral agents are a fraction of what inpatient treatment costs. A cost analysis of antibiotic prophylaxis for spontaneous bacterial peritonitis in patients with cirrhosis and ascites found that prophylaxis, particularly when targeted at high-risk patients, was clearly cost-effective compared to no prophylaxis.²⁶

The caveat, as researchers note, is that the cost calculus changes if you factor in the societal costs of promoting antibiotic resistance. A cheap antibiotic that works today but accelerates resistance, making future infections harder to treat across the whole population, may not look as attractive when the bill comes due over decades. This is a genuine tension in medicine: the individual patient clearly benefits from prophylaxis now, but the broader consequence is harder to quantify and easier to defer.

When the Evidence Gets Thin

A striking feature of lifelong antibiotic therapy is how much of it rests on limited trial data. The practice of prescribing long-term antibiotics for many conditions has outpaced the evidence base, particularly for very long durations. Trials of inhaled antibiotics in cystic fibrosis, for instance, extend to about three years at most, even though patients may be on them for decades.⁸ For post-splenectomy prophylaxis, clinical guidelines vary on how long to continue, with some recommending lifelong use and others suggesting it can be stopped after a few years in low-risk adults. The reason for the disagreement is that no one has run a decades-long randomized trial of daily penicillin in splenectomized patients and probably never will.

What fills the gap is clinical experience, observational data, and the understanding that for certain conditions, the risk of stopping antibiotics is catastrophic and the risk of continuing is manageable. This is a reasonable position, but it is worth being clear-eyed about: for many patients on lifelong antibiotics, the evidence supporting the first year or two of therapy is solid, and the evidence supporting year twenty is mostly extrapolation.

Alternatives on the Horizon

Given the downsides of indefinite antibiotic use, researchers are actively pursuing alternatives. Bacteriophage therapy, which uses viruses that specifically target and kill bacteria, has attracted significant attention as a potential substitute for chronic antibiotic suppression. Phage therapy has been applied in localized infections including otitis, infected burns, and bone and joint infections, though it remains largely experimental in most countries and is not yet a standard option for long-term prophylaxis.²⁷

For urinary tract infections specifically, other non-antibiotic approaches under study include cranberry products, D-mannose, vaginal estrogen for postmenopausal women, and intravesical treatments. None of these has yet demonstrated the same level of evidence as antibiotic prophylaxis, but for patients uncomfortable with indefinite antibiotic use, they represent an active area of clinical research. The hope is that at least some patients currently on lifelong antibiotics could eventually transition to non-antibiotic prevention strategies, reserving antibiotics for acute flare-ups rather than continuous use. For conditions like immune deficiency or post-splenectomy vulnerability, though, there is no realistic non-antibiotic substitute on the near horizon, and daily prophylaxis remains the standard of care.